StockWatch
·

CERUS CORP Q2 FY26 Results

CERSQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue57.447.0%9.5%
Total Income57.447.0%9.5%
Expenditure59.309.8%6.1%
PBT-2.8985.3%48.8%
Net Profit-2.9479.3%48.5%
OPM-3.23%2.57pp3.29pp
NPM-5.12%2.06pp5.76pp
EPS-0.010.0%66.7%
View full financials

Cerus Corporation Announces Second Quarter 2026 Financial Results

31 Jul 2026 · 31 Jul, 1:38 am

Summary

Cerus Corporation announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $63.3 million, a 5% increase year-over-year, with product revenue growing 10% to $57.4 million. Demand for its INTERCEPT Fibrinogen Complex (IFC) saw a significant increase of approximately 20% in volume. The company raised its full-year 2026 product revenue guidance to a range of $229 million to $231 million. Management highlighted progress in expanding patient access to safer blood components globally, particularly noting the strong performance and value proposition of the IFC franchise.

Key Highlights

  1. 1

    Cerus Corporation reported second quarter 2026 total revenue of $63.3 million, a 5% increase year-over-year.

  2. 2

    Product revenue for the second quarter of 2026 was $57.4 million, up 10% year-over-year, driven by increases across all product categories.

  3. 3

    Demand for INTERCEPT Fibrinogen Complex (IFC) increased, with second quarter volumes up approximately 20% compared to the prior year period.

  4. 4

    The company submitted a PMA for the INTERCEPT Blood System for Platelets with INT200 Illuminator to the FDA as planned.

  5. 5

    Cerus Corporation raised the lower end of its 2026 product revenue guidance to a range of $229 million to $231 million.

  6. 6

    Non-GAAP adjusted EBITDA for the second quarter of 2026 was positive $3.0 million, compared to positive $0.9 million in the prior year period.

  7. 7

    Cash, cash equivalents, and short-term investments were $56.3 million at June 30, 2026.

Management Comments

V

Vivek Jayaraman

This quarter we made significant progress in expanding patient access to safer blood components around the globe. I’m particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for blood centers, hospitals and clinicians is resonating and leading to earlier patient access to fibrinogen across the country. We view IFC as a compelling growth driver for Cerus.

Informational and educational content only. Not investment advice.